<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210511051258N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-02-13</date_registration>
      <primary_sponsor>Birjand University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of two types of intra-articular knee injections</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of two types of intra-articular injections including hyaluronic acid and corticosteroids in patients with mild to moderate knee osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56515</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Assignment of patients in two groups will be using the random number table method. In this way, the researcher puts his hand on one of the numbers and starts moving in the right direction and records the numbers and assigns them to different groups. If he reaches an even number on the way, the person goes to the treatment group and if he reaches the number, the patient Will be placed in the control group. Based on the sample size of the research, a number of envelopes with aluminum wrappers are prepared in order to obscure the contents of the envelopes, and each of the random sequences created is recorded on a card, and the cards are placed in the envelopes respectively. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface, and finally the letter envelopes are glued and placed in a box, respectively, at the beginning of the registration of participants. According to the order of entry of eligible participants in the study, one of the envelopes will be opened in order and the assigned group of the participant will be revealed, the first group will be treated with glucocorticoids and the second group will be treated with hyaluronic acid.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Injection of hyaluronic acid into the knee joint. Hyaluronic acid will be  high molecular weight and will be injected once. The hyaluronic acid used will be of Iranian type and with Viscor brand from Nitka company. All injections will be performed by a physician to reduce any discrepancies in the type of injection to zero . Intervention 2: Control group: Intra-knee corticosteroid injection. The glucocorticoid used to treat these people is triamcinolone acetonide, which is FDA approved. In this group, 1 injection of corticosteroids in the amount of 1ml and 40mg is performed. The corticosteroid used is of the Iranian type and will be from Exir Company.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentified individuals

When:
Access period starts 3 months after the results are published

To whom:
Study data will be available to researchers working in academia and in industry, and who can apply for it.

Conditions:
The use of documents in articles and industry and medical applications will be allowed. Analyzes on data are also allowed.

Where to obtain:
To receive the required documents and data, you can send your request via the following e-mail: nn.mahdy10@gmail.com alireza.ghoreighi@bums.ac.ir

How to obtain:
After submitting the application in the announced manner and stating the reason for the request, the applicant must wait for the researcher to respond and obtain permission from the sponsoring body, after which, if agreed, the documents and data will be sent to him.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Alireza ghoreishi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghaffari St., Birjand University of Medical Sciences</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۷۱۷۸۵۳۵۷۷</zip>
        <telephone>098 56 32395000</telephone>
        <email>alireza.ghoreishi@bums.ac.ir</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Alireza ghoreishi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ghaffari St., Birjand University of Medical Sciences</address>
        <city>Birjand</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۷۱۷۸۵۳۵۷۷</zip>
        <telephone>+98 56 3239 5000</telephone>
        <email>alireza.ghoreishi@bums.ac.ir</email>
        <affiliation>Birjand University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Be between 50 and 70 years old.
Have a visual acuity scale (VAS) score greater than 4 in the knee joint at the start of treatment.
Absence of inflammatory joint disease
Proof of osteoarthritis in patients with a WOMAC score of at least 60 out of 96</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Withdraw from the study
Existence of severe cardiovascular diseases
Existence of active infection and immune disorders
People who are very young
People with chronic diseases such as diabetes and hypertension, secondary osteoarthritis, systemic disorders, coagulopathies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Injection of hyaluronic acid into the knee joint. Hyaluronic acid will be  high molecular weight and will be injected once. The hyaluronic acid used will be of Iranian type and with Viscor brand from Nitka company. All injections will be performed by a physician to reduce any discrepancies in the type of injection to zero .</i_keyword>
      <i_keyword>Control group: Intra-knee corticosteroid injection. The glucocorticoid used to treat these people is triamcinolone acetonide, which is FDA approved. In this group, 1 injection of corticosteroids in the amount of 1ml and 40mg is performed. The corticosteroid used is of the Iranian type and will be from Exir Company.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The amount of pain in the knee joints. Timepoint: Visual analog scale score measurement at the beginning of the study and 6 weeks later. Method of measurement: visual analog scale.</prim_outcome>
      <prim_outcome>Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC). Timepoint: WOMAC score set at the beginning of the study and 6 weeks later. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index questionnaire (WOMAC).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain intensity score. Timepoint: Pain intensity measurement at the beginning of the study and 6 weeks later. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC).</sec_outcome>
      <sec_outcome>Intensity of joint stiffness. Timepoint: Measurement of joint stiffness at the beginning of the study and 6 weeks later. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC).</sec_outcome>
      <sec_outcome>Ability to perform daily activities score. Timepoint: Scoring the ability to perform daily activities at the beginning of the study and 6 weeks later. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Birjand University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-01</approval_date>
        <contact_name>Research Ethics Committees of Birjand University of Medical Sciences</contact_name>
        <contact_address>Ghaffari blvd, birjand medical university Birjand South Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
